Frontiers in Medical Science Research, 2025, 7(3); doi: 10.25236/FMSR.2025.070302.
Cun Xu1, Jianxin Lyu2
1College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
2Key Laboratory of Laboratory Medicine, Ministry of Education, College of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
ANXA2, a calcium-dependent phospholipid-binding protein, regulates critical physiological processes such as membrane trafficking, signal transduction, and cell adhesion. While accumulating evidence implicates ANXA2 in tumor progression across multiple malignancies, its functional and prognostic significance in glioma remains poorly defined. In this study, we utilized The Cancer Genome Atlas (TCGA), the Genotypic Tissue Expression (GTEx) database, and the Chinese Glioma Genome Atlas (CGGA) to investigate the associations between ANXA2 and clinicopathological and molecular features of glioma patients, as well as the correlation of patient prognosis. Our study showed that high expression of ANXA2 was significantly associated with poor patient prognosis. Further analysis of the biological role of ANXA2 in gliomas revealed that ANXA2 is involved in a variety of biological processes involved in glioma development, including immune responses, cellular activation, and modulation of immune system defenses. Immuno-infiltration analysis of the TIMER database revealed a correlation between high ANXA2 expression and infiltration of various immune cells as well as immune checkpoints in glioma. In summary, ANXA2 represents a promising potential biomarker for clinical diagnosis and therapeutic targeting in glioma.
glioma, ANXA2, prognosis, biomarker
Cun Xu, Jianxin Lyu. ANXA2 is a Potential Biomarker Associated with Poor Prognosis in Glioma. Frontiers in Medical Science Research (2025), Vol. 7, Issue 3: 8-16. https://doi.org/10.25236/FMSR.2025.070302.
[1] Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma[J]. Nat Rev Clin Oncol, 2018, 15(7): 422-442.
[2] Chen R, Smith-Cohn M, Cohen A L, et al. Glioma Subclassifications and Their Clinical Significance[J]. Neurotherapeutics, 2017, 14(2): 284-297.
[3] Śledzińska P, Bebyn M G, Furtak J, et al. Prognostic and Predictive Biomarkers in Gliomas[J]. Int J Mol Sci, 2021, 22(19).
[4] Schaff L R, Mellinghoff I K. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review[J]. Jama, 2023, 329(7): 574-587.
[5] Ma S, Lu C C, Yang L Y, et al. ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis[J]. J Exp Clin Cancer Res, 2018, 37(1): 183.
[6] Bharadwaj A G, Kempster E, Waisman D M. The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor[J]. Biomolecules, 2021, 11(12).
[7] Hajjar K A, Jacovina A T, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II[J]. J Biol Chem, 1994, 269(33): 21191-7.
[8] Maule F, Bresolin S, Rampazzo E, et al. Annexin 2A sustains glioblastoma cell dissemination and proliferation[J]. Oncotarget, 2016, 7(34): 54632-54649.
[9] Wu B, Zhang F, Yu M, et al. Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells[J]. Cell Prolif, 2012, 45(3): 189-98.
[10] GTEx Consortium. The Genotype-Tissue Expression (GTEx) project[J]. Nat Genet, 2013, 45(6): 580-5.
[11] Gao J, Aksoy B A, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1.
[12] Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-w514.
[13] Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-w560.
[14] Thul P J, Lindskog C. The human protein atlas: A spatial map of the human proteome[J]. Protein Sci, 2018, 27(1): 233-244.
[15] Chen B, Khodadoust M S, Liu C L, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT[J]. Methods Mol Biol, 2018, 1711: 243-259.
[16] Appin C L, Brat D J. Biomarker-driven diagnosis of diffuse gliomas[J]. Mol Aspects Med, 2015, 45: 87-96.
[17] Ding X, Zhang L, Fan M, et al. TME-NET: an interpretable deep neural network for predicting pan-cancer immune checkpoint inhibitor responses[J]. Brief Bioinform, 2024, 25(5).
[18] Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review[J]. J Clin Neurosci, 2018, 54: 7-13.
[19] Jackson C M, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma[J]. Nat Immunol, 2019, 20(9): 1100-1109.
[20] Bikfalvi A, Da Costa C A, Avril T, et al. Challenges in glioblastoma research: focus on the tumor microenvironment[J]. Trends Cancer, 2023, 9(1): 9-27.
[21] Huang Y, Jia M, Yang X, et al. Annexin A2: The diversity of pathological effects in tumorigenesis and immune response[J]. Int J Cancer, 2022, 151(4): 497-509.
[22] Huang B, Zhang J, Zong W, et al. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies[J]. Front Immunol, 2023, 14: 994698.